Avastin news from FiercePharma
NewsBreast-cancer uptake boosts Avastin sales
Avastin may have lost its chance to go on the U.K.'s National Health Service formulary, but it's still blowing past sales expectations. Wall Street analysts are saying that faster-than-expected Read more...
More NICE debate over cancer meds
It's not just Roche that refused to fork over cost-effectiveness info on its cancer med to the U.K.'s National Institution for Clinical Health and Excellence. So, too, has Merck Serono. Yesterday, Read more...
Roche, NICE in Avastin data standoff
It's another blow for Roche's Avastin the U.K. The National Institute for Clinical Health and Excellence shot down the high-tech cancer med as a first-line treatment for lung and breast cancer, Read more...
FDA: Don't blame us for Avastin change
Remember last year when Genentech said it wouldn't sell its cancer med Avastin to compounding pharmacies, which repackage it for off-label use in patients with macular degeneration -- and then blamed Read more...
Erbitux, KRAS gene star at ASCO
As expected, headlines have been spewing from the American Society of Clinical Oncology meeting like ash from a volcano. And as promised, we bring you a roundup of the latest and greatest on using Read more...
ASCO already churning out news
Today marks the start of the annual American Society of Clinical Oncology meeting, always a big news generator in the pharma biz. We'll let our sister pub FierceBiotech keep you up to date on the Read more...
Avastin-Lucentis trial may reshape pharma
We thought the head-to-head trial of Avastin and Lucentis for age-related macular degeneration was a big deal for Genentech, which Read more...
BMS swallows Canada's Erbitux price
Call it a new pricing strategy. Bristol-Myers Squibb is preparing to launch the cancer treatment Erbitux in Canada after a two-year wrangle over cost. Approved by Health Canada in September 2005, Read more...
Stanley: Erbitux outperformed Avastin
Morgan Stanley got a juicy scoop on the Avastin versus Erbitux boxing match: Genentech's Avastin faces news that as-yet-unpublished data shows Erbitux delivering an "unexpected survival Read more...
Pfizer, Roche suffer as big drugs falter
Today's earnings roundup is a snapshot of pharma's challenges--generic Read more...
| Press ReleasesPRESS RELEASE: Antisoma Shares Slide as Novartis Corporation (NVS) Sets up Avastin Fight Antisoma Shares Slide as Novartis Corporation Sets up Avastin Fight LONDON--Nov 20, 2007 -- ASA404 phase III lung cancer trial to include broader range of patients London, UK: 20 November 2007 - Read more... PRESS RELEASE: Genentech, Says Avastin Shows Promise for Brain Cancer Genentech, Says Avastin Shows Promise for Brain Cancer DALLAS -- Genentech today announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin® (bevacizumab) Read more... PRESS RELEASE: Genentech President Defends Company’s Decision to Embargo Avastin Sales to Compounding Pharmacies Genentech President Defends Company’s Decision to Embargo Avastin Sales to Compounding Pharmacies Susan Desmond-Hellmann, MD, MPH, president of product development for Genentech, said she came to Read more... PRESS RELEASE: Genentech Announces Resubmission of sBLA for Avastin in Combination with Paclitaxel Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer Genentech announced Read more... |
Get more Avastin coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends